Compare PCVX & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCVX | BIO |
|---|---|---|
| Founded | 2013 | 1952 |
| Country | United States | United States |
| Employees | N/A | 7450 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.7B | 7.1B |
| IPO Year | 2020 | N/A |
| Metric | PCVX | BIO |
|---|---|---|
| Price | $62.79 | $292.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 4 |
| Target Price | $88.25 | ★ $339.75 |
| AVG Volume (30 Days) | ★ 1.2M | 273.6K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $2.59 |
| Revenue Next Year | N/A | $3.21 |
| P/E Ratio | ★ N/A | $9.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.09 | $211.43 |
| 52 Week High | $65.00 | $343.12 |
| Indicator | PCVX | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 65.54 | 64.35 |
| Support Level | $42.30 | $256.85 |
| Resistance Level | $65.00 | $311.09 |
| Average True Range (ATR) | 2.28 | 7.57 |
| MACD | 0.62 | 2.28 |
| Stochastic Oscillator | 95.44 | 90.94 |
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.